Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;36(10):3009-14.
doi: 10.2337/dc12-2197. Epub 2013 Jun 4.

Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications

Gillian E Caughey  1 , Adrian K Preiss, Agnes I Vitry, Andrew L Gilbert, Elizabeth E Roughead
Affiliations

Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications

Gillian E Caughey et al. Diabetes Care. 2013 Oct.

Abstract

Objective: To identify if there is a dose-dependent risk of diabetes complications in patients treated with corticosteroids who have both diabetes and chronic obstructive pulmonary disorder (COPD).

Research design and methods: A retrospective study of administrative claims data from the Australian Government Department of Veterans' Affairs, from 1 July 2001 to 30 June 2008, of diabetes patients newly initiated on metformin or sulfonylurea. COPD was identified by dispensings of tiotropium or ipratropium in the 6 months preceding study entry. Total corticosteroid use (inhaled and systemic) in the 12 months after study entry was determined. The outcome was time to hospitalization for a diabetes-related complication. Competing risks and Cox proportional hazard regression analyses were conducted with adjustment for a number of covariates.

Results: A total of 18,226 subjects with diabetes were identified, of which 5.9% had COPD. Of those with COPD, 67.2% were dispensed corticosteroids in the 12 months from study entry. Stratification by dose of corticosteroids demonstrated a 94% increased likelihood of hospitalization for a diabetes complication for those who received a total defined daily dose (DDD) of corticosteroids≥0.83/day (subhazard ratio 1.94 [95% CI 1.14-3.28], P=0.014), by comparison with those who did not receive a corticosteroid. Lower doses of corticosteroid (<0.83 DDD/day) were not associated with an increased risk of diabetes-related hospitalization.

Conclusions: In patients with diabetes and COPD, an increased risk of diabetes-related hospitalizations was only evident with use of high doses of corticosteroids. This highlights the need for constant revision of corticosteroid dose in those with diabetes and COPD, to ensure that the minimally effective dose is used, together with review of appropriate response to therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flowchart of diabetes and COPD cohort selection.
Figure 2
Figure 2
Cumulative incidence of time to hospitalization for a diabetes complication stratified by total cumulative dose (DDD) of corticosteroids in the 12 months from study entry.
See this image and copyright information in PMC

References

    1. Kerr EA, Heisler M, Krein SL, et al. Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients’ treatment priorities and self-management? J Gen Intern Med 2007;22:1635–1640 - PMC - PubMed
    1. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract 2010;87:385–393 - PubMed
    1. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 2006;29:725–731 - PubMed
    1. Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M. Multimorbidity’s many challenges. BMJ 2007;334:1016–1017 - PMC - PubMed
    1. Rabe KF, Wedzicha JA. Controversies in treatment of chronic obstructive pulmonary disease. Lancet 2011;378:1038–1047 - PubMed

Publication types

Substances